• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.肾细胞癌患者中调节性T细胞的频率及其与生存相关性的研究
Cancer Immunol Immunother. 2007 Nov;56(11):1743-53. doi: 10.1007/s00262-007-0318-z. Epub 2007 May 9.
2
Frequency and gene expression profile of regulatory T cells in renal cell carcinoma.肾细胞癌中调节性T细胞的频率和基因表达谱
Tumour Biol. 2009;30(3):160-70. doi: 10.1159/000228909. Epub 2009 Jul 16.
3
Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.调节性 T 细胞、白细胞介素 (IL)-6、IL-8、血管内皮生长因子 (VEGF)、CXCL10、CXCL11、表皮生长因子 (EGF) 和肝细胞生长因子 (HGF) 作为肾细胞癌患者宿主免疫的替代标志物。
BJU Int. 2013 Sep;112(5):686-96. doi: 10.1111/bju.12068. Epub 2013 Mar 15.
4
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.肿瘤浸润性Foxp3阴性CD4阳性CD25阳性T细胞预示肾细胞癌患者预后不良。
Clin Cancer Res. 2007 Apr 1;13(7):2075-81. doi: 10.1158/1078-0432.CCR-06-2139.
5
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.接受高剂量白细胞介素-2治疗的转移性黑色素瘤或肾细胞癌患者中CD4+CD25+调节性T细胞的特征分析
J Clin Oncol. 2006 Mar 1;24(7):1169-77. doi: 10.1200/JCO.2005.03.6830.
6
Effect of Peripheral Blood CD4 + CD25 + Regulatory T Cell on Postoperative Immunotherapy for Patients with Renal Carcinoma.外周血CD4+CD25+调节性T细胞对肾癌患者术后免疫治疗的影响
Asian Pac J Cancer Prev. 2016;17(4):2027-30. doi: 10.7314/apjcp.2016.17.4.2027.
7
Down syndrome, autoimmunity and T regulatory cells.唐氏综合征、自身免疫与调节性 T 细胞。
Clin Exp Immunol. 2012 Sep;169(3):238-43. doi: 10.1111/j.1365-2249.2012.04610.x.
8
Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells.用与霍乱毒素B亚基偶联的抗原诱导口服耐受可产生Foxp3 + CD25 +和Foxp3 - CD25 - CD4 +调节性T细胞。
J Immunol. 2006 Dec 1;177(11):7634-44. doi: 10.4049/jimmunol.177.11.7634.
9
Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.人肾细胞癌中新鲜(未培养)肿瘤浸润性T淋巴细胞的表型、细胞因子产生及细胞溶解能力
Clin Exp Immunol. 1997 Sep;109(3):501-9. doi: 10.1046/j.1365-2249.1997.4771375.x.
10
Low frequency of GITR+ T cells in ex vivo and in vitro expanded Treg cells from type 1 diabetic patients.1 型糖尿病患者体外扩增的 Treg 细胞中 GITR+ T 细胞频率较低。
Int Immunol. 2013 Oct;25(10):563-74. doi: 10.1093/intimm/dxt020. Epub 2013 Aug 8.

引用本文的文献

1
Regulatory T cells in the tumour microenvironment.肿瘤微环境中的调节性T细胞。
Nat Rev Cancer. 2025 Jun 10. doi: 10.1038/s41568-025-00832-9.
2
Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma.探索肾细胞癌中前转移微环境的分子和细胞机制。
Mol Cancer. 2025 Apr 22;24(1):121. doi: 10.1186/s12943-025-02315-9.
3
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients.细胞和分泌蛋白质组分析揭示肾细胞癌患者预后中的免疫生物标志物。
Oncoimmunology. 2025 Dec;14(1):2481109. doi: 10.1080/2162402X.2025.2481109. Epub 2025 Mar 24.
4
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.功能重编程的调节性 T 细胞(Tregs)产生 IFNγ 可增强 OX40/CD137 双特异性激动剂疗法的抗肿瘤疗效。
Cancer Res Commun. 2024 Aug 1;4(8):2045-2057. doi: 10.1158/2767-9764.CRC-23-0500.
5
Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group.免疫疗法与立体定向体部放疗用于不适于手术或拒绝肾切除术的老年非转移性肾癌患者:国际老年放疗小组的实用建议
Front Oncol. 2024 May 24;14:1391464. doi: 10.3389/fonc.2024.1391464. eCollection 2024.
6
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.靶向 CXCR4 通过 PTEN 抑制肾癌患者 T 调节细胞功能。
Br J Cancer. 2024 Jun;130(12):2016-2026. doi: 10.1038/s41416-024-02702-x. Epub 2024 May 4.
7
Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.卡博替尼联合免疫检查点抑制剂治疗肾细胞癌:一项系统评价和荟萃分析。
Front Pharmacol. 2024 Apr 17;15:1322473. doi: 10.3389/fphar.2024.1322473. eCollection 2024.
8
Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma.犬肾细胞癌中 CD3、FoxP3 和 granzyme B 免疫染色的定量分析。
Vet Immunol Immunopathol. 2024 May;271:110741. doi: 10.1016/j.vetimm.2024.110741. Epub 2024 Mar 16.
9
Current status and future perspective of immunotherapy for renal cell carcinoma.肾细胞癌免疫治疗的现状与展望。
Int J Clin Oncol. 2024 Aug;29(8):1105-1114. doi: 10.1007/s10147-023-02446-3. Epub 2023 Dec 18.
10
Acquisition of suppressive function by conventional T cells limits antitumor immunity upon T depletion.常规 T 细胞获得抑制功能会限制 T 细胞耗竭后抗肿瘤免疫。
Sci Immunol. 2023 Dec 15;8(90):eabo5558. doi: 10.1126/sciimmunol.abo5558.

本文引用的文献

1
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.CD127的表达与人类CD4+调节性T细胞的FoxP3及抑制功能呈负相关。
J Exp Med. 2006 Jul 10;203(7):1701-11. doi: 10.1084/jem.20060772. Epub 2006 Jul 3.
2
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells.白细胞介素(IL)-2和IL-7受体的表达可区分人类调节性T细胞和活化T细胞。
J Exp Med. 2006 Jul 10;203(7):1693-700. doi: 10.1084/jem.20060468. Epub 2006 Jul 3.
3
Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.肺癌和胸膜间皮瘤患者外周血中表达Foxp3的CD4+CD25+和CD8+CD28-调节性T细胞。
Hum Immunol. 2006 Jan-Feb;67(1-2):1-12. doi: 10.1016/j.humimm.2005.11.005. Epub 2006 Mar 31.
4
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.肿瘤通过将CD4+CD25-淋巴细胞转化来诱导调节性T细胞扩增,此过程不依赖胸腺和增殖。
Cancer Res. 2006 Apr 15;66(8):4488-95. doi: 10.1158/0008-5472.CAN-05-4217.
5
Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells.磁珠分离的人CD4+CD25+调节性T细胞呈无反应性,且能显著抑制CD4+CD25-T反应细胞的增殖。
Clin Immunol. 2006 Aug;120(2):232-3. doi: 10.1016/j.clim.2006.02.007. Epub 2006 Apr 3.
6
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.在CD4细胞群减少的情况下,调节性T细胞比例增加,这解释了恶性胶质瘤患者的细胞免疫缺陷。
Cancer Res. 2006 Mar 15;66(6):3294-302. doi: 10.1158/0008-5472.CAN-05-3773.
7
Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.接受高剂量白细胞介素-2治疗的转移性黑色素瘤或肾细胞癌患者中CD4+CD25+调节性T细胞的特征分析
J Clin Oncol. 2006 Mar 1;24(7):1169-77. doi: 10.1200/JCO.2005.03.6830.
8
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.多发性骨髓瘤患者体内初始CD4+CD25高表达FoxP3+调节性T细胞的外周扩增
Blood. 2006 May 15;107(10):3940-9. doi: 10.1182/blood-2005-09-3671. Epub 2006 Jan 12.
9
Effect of CD4+CD25+ and CD4+CD25- T regulatory cells on the generation of cytolytic T cell response to a self but human tumor-associated epitope in vitro.CD4+CD25+和CD4+CD25-调节性T细胞对体外针对自身但人肿瘤相关表位的细胞毒性T细胞反应生成的影响。
J Immunol. 2006 Jan 15;176(2):984-90. doi: 10.4049/jimmunol.176.2.984.
10
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.调节性T细胞特异性叉头框转录因子FoxP3的表达与卵巢癌的不良预后相关。
Clin Cancer Res. 2005 Dec 1;11(23):8326-31. doi: 10.1158/1078-0432.CCR-05-1244.

肾细胞癌患者中调节性T细胞的频率及其与生存相关性的研究

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.

作者信息

Griffiths Richard W, Elkord Eyad, Gilham David E, Ramani Vijay, Clarke Noel, Stern Peter L, Hawkins Robert E

机构信息

Department of Medical Oncology, Christie Research Centre, Paterson Institute for Cancer Research, Manchester, UK.

出版信息

Cancer Immunol Immunother. 2007 Nov;56(11):1743-53. doi: 10.1007/s00262-007-0318-z. Epub 2007 May 9.

DOI:10.1007/s00262-007-0318-z
PMID:17487490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11030591/
Abstract

BACKGROUND

Regulatory T cells are important in maintaining immune homeostasis, mediating peripheral tolerance and preventing autoimmunity. Increased frequencies of CD4(+)CD25(high )T regulatory (T(Reg)) cells have been documented in the peripheral blood of patients with several types of cancer consistent with a role in tumour escape from immunological control. We have investigated the presence of T(Reg) cells systemically and in situ in previously untreated patients with renal cell carcinoma (RCC).

RESULTS

We have shown that there is a significant increased frequency of CD4(+)CD25(high) T cells in RCC patients (n = 49) compared to normal donors (n = 38), respectively, 2.47% versus 1.50%; P < 0.0001. We confirmed these data using the FOXP3 marker of T(Reg) cells in a subset of these patients and normal donors. The population of T(Reg) cells identified showed the expected phenotype with CD4(+)CD25(high) population in both RCC patients and normal donors contained higher proportions of CD45RO and GITR than CD4(+)CD25(-/low) populations and exhibiting suppressive activity in an anti-CD3 and anti-CD28 induced proliferation assay. CD4(+)FOXP3(+) T cells were detected in the tumour microenvironment by immunofluorescence and the numbers enumerated in lymphocytes recovered following enzymatic disaggregations of biopsies; their frequency was higher in the tumour than the peripheral blood of the same patients. The early follow up data show an association between higher peripheral blood regulatory T-cell count and adverse overall survival.

CONCLUSION

These data confirm the increase of T(Reg) cells in RCC patients and provide impetus to further investigate modulation of T(Reg) activity in RCC patients as part of therapy.

摘要

背景

调节性T细胞在维持免疫稳态、介导外周耐受和预防自身免疫方面起着重要作用。在几种类型癌症患者的外周血中,已发现CD4(+)CD25(高)调节性T(T(Reg))细胞频率增加,这与肿瘤逃避免疫控制的作用一致。我们研究了肾细胞癌(RCC)初治患者体内及原位T(Reg)细胞的存在情况。

结果

我们发现,与正常供者(n = 38)相比,RCC患者(n = 49)中CD4(+)CD25(高) T细胞频率显著增加,分别为2.47%和1.50%;P < 0.0001。我们在这些患者和正常供者的一个亚组中使用T(Reg)细胞的FOXP3标志物证实了这些数据。所鉴定的T(Reg)细胞群体显示出预期的表型,RCC患者和正常供者中的CD4(+)CD25(高)群体比CD4(+)CD25(-/低)群体含有更高比例的CD45RO和糖皮质激素诱导的肿瘤坏死因子受体(GITR),并在抗CD3和抗CD28诱导的增殖试验中表现出抑制活性。通过免疫荧光在肿瘤微环境中检测到CD4(+)FOXP3(+) T细胞,并对活检组织酶解后回收的淋巴细胞进行计数;同一患者肿瘤中的频率高于外周血。早期随访数据显示外周血调节性T细胞计数较高与不良总生存之间存在关联。

结论

这些数据证实了RCC患者中T(Reg)细胞增加,并为进一步研究作为治疗一部分调节RCC患者T(Reg)活性提供了动力。